A citation-based method for searching scientific literature

Paul M Ridker, Christopher P Cannon, David Morrow, Nader Rifai, Lynda M Rose, Carolyn H McCabe, Marc A Pfeffer, Eugene Braunwald. N Engl J Med 2005
Times Cited: 1694







List of co-cited articles
750 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Paul M Ridker, Brendan M Everett, Tom Thuren, Jean G MacFadyen, William H Chang, Christie Ballantyne, Francisco Fonseca, Jose Nicolau, Wolfgang Koenig, Stefan D Anker,[...]. N Engl J Med 2017
53

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction.
Jean-Claude Tardif, Simon Kouz, David D Waters, Olivier F Bertrand, Rafael Diaz, Aldo P Maggioni, Fausto J Pinto, Reda Ibrahim, Habib Gamra, Ghassan S Kiwan,[...]. N Engl J Med 2019
819
36

Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Elaine Zaharris, Virak Mam, Ahmed Hasan, Yves Rosenberg, Erin Iturriaga,[...]. N Engl J Med 2019
526
31

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker, Eleanor Danielson, Francisco A H Fonseca, Jacques Genest, Antonio M Gotto, John J P Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen,[...]. N Engl J Med 2008
30

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Steven E Nissen, E Murat Tuzcu, Paul Schoenhagen, Tim Crowe, William J Sasiela, John Tsai, John Orazem, Raymond D Magorien, Charles O'Shaughnessy, Peter Ganz. N Engl J Med 2005
21

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Erin A Bohula, Robert P Giugliano, Christopher P Cannon, Jing Zhou, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Michael A Blazing, Eugene Braunwald. Circulation 2015
186
21


Low-dose colchicine for secondary prevention of cardiovascular disease.
Stefan M Nidorf, John W Eikelboom, Charley A Budgeon, Peter L Thompson. J Am Coll Cardiol 2013
468
19

Colchicine in Patients with Chronic Coronary Disease.
Stefan M Nidorf, Aernoud T L Fiolet, Arend Mosterd, John W Eikelboom, Astrid Schut, Tjerk S J Opstal, Salem H K The, Xiao-Fang Xu, Mark A Ireland, Timo Lenderink,[...]. N Engl J Med 2020
384
19

NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.
Peter Duewell, Hajime Kono, Katey J Rayner, Cherilyn M Sirois, Gregory Vladimer, Franz G Bauernfeind, George S Abela, Luigi Franchi, Gabriel Nuñez, Max Schnurr,[...]. Nature 2010
15

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Marc S Sabatine, Robert P Giugliano, Anthony C Keech, Narimon Honarpour, Stephen D Wiviott, Sabina A Murphy, Julia F Kuder, Huei Wang, Thomas Liu, Scott M Wasserman,[...]. N Engl J Med 2017
15

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.
P M Ridker, N Rifai, M Clearfield, J R Downs, S E Weis, J S Miles, A M Gotto. N Engl J Med 2001
14



Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Gregory G Schwartz, P Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Jay M Edelberg, Shaun G Goodman, Corinne Hanotin, Robert A Harrington,[...]. N Engl J Med 2018
13


Progress and challenges in translating the biology of atherosclerosis.
Peter Libby, Paul M Ridker, Göran K Hansson. Nature 2011
12

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.
Brian A Ference, Henry N Ginsberg, Ian Graham, Kausik K Ray, Chris J Packard, Eric Bruckert, Robert A Hegele, Ronald M Krauss, Frederick J Raal, Heribert Schunkert,[...]. Eur Heart J 2017
12

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Paul M Ridker, Eleanor Danielson, Francisco Ah Fonseca, Jacques Genest, Antonio M Gotto, John Jp Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G Macfadyen,[...]. Lancet 2009
730
12

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis.
Stephen Kaptoge, Emanuele Di Angelantonio, Gordon Lowe, Mark B Pepys, Simon G Thompson, Rory Collins, John Danesh. Lancet 2010
12


Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial.
Michelle L O'Donoghue, Eugene Braunwald, Harvey D White, Mary Ann Lukas, Elizabeth Tarka, P Gabriel Steg, Judith S Hochman, Christoph Bode, Aldo P Maggioni, KyungAh Im,[...]. JAMA 2014
287
11



Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Christopher P Cannon, Eugene Braunwald, Carolyn H McCabe, Daniel J Rader, Jean L Rouleau, Rene Belder, Steven V Joyal, Karen A Hill, Marc A Pfeffer, Allan M Skene. N Engl J Med 2004
11

Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
David A Morrow, James A de Lemos, Marc S Sabatine, Stephen D Wiviott, Michael A Blazing, Amy Shui, Nader Rifai, Robert M Califf, Eugene Braunwald. Circulation 2006
234
11

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.
François Mach, Colin Baigent, Alberico L Catapano, Konstantinos C Koskinas, Manuela Casula, Lina Badimon, M John Chapman, Guy G De Backer, Victoria Delgado, Brian A Ference,[...]. Eur Heart J 2020
11

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
P M Ridker, M Cushman, M J Stampfer, R P Tracy, C H Hennekens. N Engl J Med 1997
10


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
10

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
10

Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Aruna D Pradhan, Aaron W Aday, Lynda M Rose, Paul M Ridker. Circulation 2018
89
11

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
Michelle L O'Donoghue, Ruchira Glaser, Matthew A Cavender, Philip E Aylward, Marc P Bonaca, Andrzej Budaj, Richard Y Davies, Mikael Dellborg, Keith A A Fox, Jorge Antonio T Gutierrez,[...]. JAMA 2016
144
10

Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Paul M Ridker, Peter Libby, Jean G MacFadyen, Tom Thuren, Christie Ballantyne, Francisco Fonseca, Wolfgang Koenig, Hiroaki Shimokawa, Brendan M Everett, Robert J Glynn. Eur Heart J 2018
219
9

The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Daniel I Swerdlow, Michael V Holmes, Karoline B Kuchenbaecker, Jorgen E L Engmann, Tina Shah, Reecha Sofat, Yiran Guo, Christina Chung, Anne Peasey, Roman Pfister,[...]. Lancet 2012
637
9

Inflammation in atherosclerosis: from pathophysiology to practice.
Peter Libby, Paul M Ridker, Göran K Hansson. J Am Coll Cardiol 2009
9

Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study.
Kaivan Vaidya, Clare Arnott, Gonzalo J Martínez, Bernard Ng, Samuel McCormack, David R Sullivan, David S Celermajer, Sanjay Patel. JACC Cardiovasc Imaging 2018
116
9


Colchicine--Update on mechanisms of action and therapeutic uses.
Ying Ying Leung, Laura Li Yao Hui, Virginia B Kraus. Semin Arthritis Rheum 2015
317
9

C-reactive protein, fibrinogen, and cardiovascular disease prediction.
Stephen Kaptoge, Emanuele Di Angelantonio, Lisa Pennells, Angela M Wood, Ian R White, Pei Gao, Matthew Walker, Alexander Thompson, Nadeem Sarwar, Muriel Caslake,[...]. N Engl J Med 2012
692
8

Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome.
Gonzalo J Martínez, Stacy Robertson, Jennifer Barraclough, Qiong Xia, Ziad Mallat, Christina Bursill, David S Celermajer, Sanjay Patel. J Am Heart Assoc 2015
157
8

Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation.
Kristiina Rajamäki, Jani Lappalainen, Katariina Oörni, Elina Välimäki, Sampsa Matikainen, Petri T Kovanen, Kari K Eklund. PLoS One 2010
592
8

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.
John Danesh, Jeremy G Wheeler, Gideon M Hirschfield, Shinichi Eda, Gudny Eiriksdottir, Ann Rumley, Gordon D O Lowe, Mark B Pepys, Vilmundur Gudnason. N Engl J Med 2004
8

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes,[...]. Lancet 2010
8

The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.
G Liuzzo, L M Biasucci, J R Gallimore, R L Grillo, A G Rebuzzi, M B Pepys, A Maseri. N Engl J Med 1994
8

Inflammatory and Cholesterol Risk in the FOURIER Trial.
Erin A Bohula, Robert P Giugliano, Lawrence A Leiter, Subodh Verma, Jeong-Gun Park, Peter S Sever, Armando Lira Pineda, Narimon Honarpour, Huei Wang, Sabina A Murphy,[...]. Circulation 2018
121
8

NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis.
Alena Grebe, Florian Hoss, Eicke Latz. Circ Res 2018
266
8

Darapladib for preventing ischemic events in stable coronary heart disease.
Harvey D White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y Davies, Andrzej Budaj, Robert A Harrington, P Gabriel Steg, Diego Ardissino,[...]. N Engl J Med 2014
353
8


Gout-associated uric acid crystals activate the NALP3 inflammasome.
Fabio Martinon, Virginie Pétrilli, Annick Mayor, Aubry Tardivel, Jürg Tschopp. Nature 2006
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.